## Natalia Mitiushkina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2480574/publications.pdf

Version: 2024-02-01

516710 477307 38 853 16 29 citations g-index h-index papers 38 38 38 1359 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Novel ALK fusion partners in lung cancer. Cancer Letters, 2015, 362, 116-121.	7.2	75
2	High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. European Journal of Cancer, 2006, 42, 1380-1384.	2.8	70
3	Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Familial Cancer, 2007, 6, 281-286.	1.9	67
4	High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. International Journal of Cancer, 2012, 130, 2867-2873.	5.1	58
5	Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Breast Cancer Research and Treatment, 2014, 145, 553-562.	2.5	51
6	Detection of <i>EGFR</i> mutations and <i>EML4â€ALK</i> rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathology, 2013, 121, 370-376.	2.4	48
7	Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. Medical Oncology, 2013, 30, 686.	2.5	43
8	High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. Onkologie, 2010, 33, 231-238.	0.8	39
9	Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Letters, 2009, 278, 183-191.	7.2	37
10	CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Research and Treatment, 2006, 100, 99-102.	2.5	32
11	Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients. Cancer Letters, 2015, 359, 259-261.	7.2	32
12	High prevalence of <i>GPRC5A</i> germline mutations in <i>BRCA1</i> nutant breast cancer patients. International Journal of Cancer, 2014, 134, 2352-2358.	5.1	31
13	Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Molecular Diagnosis and Therapy, 2016, 20, 401-406.	3.8	30
14	High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas. Breast Cancer Research and Treatment, 2012, 131, 1049-1059.	2.5	25
15	Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors. Pediatric Blood and Cancer, 2020, 67, e28220.	1.5	24
16	Effect of genotype and methylation of CYP2D6 on smoking behaviour. Pharmacogenetics and Genomics, 2015, 25, 531-540.	1.5	17
17	Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan. Journal of Gastrointestinal Cancer, 2016, 47, 502-505.	1.3	16
18	Spectrum of APC and MUTYH germâ€line mutations in Russian patients with colorectal malignancies. Clinical Genetics, 2018, 93, 1015-1021.	2.0	16

#	Article	IF	Citations
19	The genotypes and methylation of MAO genes as factors behind smoking behavior. Pharmacogenetics and Genomics, 2017, 27, 394-401.	1.5	14
20	Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants. Biochimie, 2018, 154, 19-24.	2.6	14
21	Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. Familial Cancer, 2013, 12, 129-132.	1.9	13
22	BRCA1 4153delA founder mutation in Russian ovarian cancer patients. Hereditary Cancer in Clinical Practice, 2006, 4, 193.	1.5	12
23	Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment. Journal of Thoracic Oncology, 2014, 9, e31-e33.	1.1	12
24	Comparative analysis of expression of mutant and wild-type alleles is essential for reliable PCR-based detection of MET exon 14 skipping. Biochimie, 2019, 165, 267-274.	2.6	10
25	First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. Clinical Drug Investigation, 2018, 38, 553-562.	2.2	8
26	EGFR T790M Mutation in TKI-Na $\tilde{A}$ -ve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts. Oncology Research and Treatment, 2018, 41, 634-642.	1.2	8
27	Comprehensive evaluation of the test for 5′′â€ad <scp>mRNA</scp> unbalanced expression as a screening tool for <scp>ALK</scp> and <scp>ROS1</scp> fusions in lung cancer. Cancer Medicine, 2022, , .	2.8	8
28	Apoptosis-deficient Pro allele of gene is associated with the resistance of psoriasis to the UV-based therapy. Journal of Dermatological Science, 2005, 37, 185-187.	1.9	7
29	Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression. Oncology Research and Treatment, 2016, 39, 605-614.	1.2	6
30	The effect of SLC6A3 variable number of tandem repeats and methylation levels on individual susceptibility to start tobacco smoking and on the ability of smokers to quit smoking. Pharmacogenetics and Genomics, 2020, 30, 117-123.	1.5	6
31	Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study. Translational Oncology, 2021, 14, 101121.	3.7	6
32	Biased detection of guanine-rich microRNAs by array profiling: Systematic error or biological phenomenon?. Journal of Computational Science, 2014, 5, 351-356.	2.9	5
33	BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. Melanoma Research, 2016, 26, 442-447.	1.2	5
34	Evidence for depletion of CASP5 Ala90Thr heterozygous genotype in aged subjects. Experimental Gerontology, 2010, 45, 726-729.	2.8	4
35	Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. Hereditary Cancer in Clinical Practice, 2009, 7, 2.	1.5	3
36	Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1. International Journal of Molecular Sciences, 2022, 23, 4586.	4.1	1

#	‡	Article	lF	CITATIONS
3	37	Role of CYP2D6 gene polymorphism in individual's ability to quit smoking. European Journal of Cancer, Supplement, 2008, 6, 206.	2.2	o
3	88	Distinct benefit from crizotinib in lung cancer patients carrying distinct ALK translocations: is fluorescent hybridization in situ testing still sufficient to guide clinical decisions?. Translational Cancer Research, 2016, 5, S1393-S1395.	1.0	0